Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Alterity Therapeutics Ltd
PRNAFCurrent price
0.0036 USD
0 USD (0.00%)
Last closed
1.15 USD
Company
alteritytherapeutics.com
ISIN
US02155X1063
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
10 515 434 USD
Yield for 12 month
-48.00 %
1Y
3Y
5Y
10Y
15Y
PRNAF
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia. Address: 350 Collins Street, Melbourne, VIC, Australia, 3000
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
7 USDP/E ratio
–Dividend Yield
–Current Year
+1 762 961 USD
Last Year
+1 715 287 USD
Current Quarter
+464 628 USD
Last Quarter
+454 206 USD
Current Year
+1 699 390 USD
Last Year
+1 648 040 USD
Current Quarter
+432 770 USD
Last Quarter
+429 050 USD
Key Figures PRNAF
1 year
3 years
5 years
10 years
EBITDA
-19 571 604 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-52.66 %
PEG Ratio
–
Return On Equity TTM
-104.47 %
Wall Street Target Price
7 USD
Revenue TTM
4 019 285 USD
Book Value
0.003 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
38.4 %
Dividend Yield
–
Gross Profit TTM
3 631 266 USD
Earnings per share
-2.07 USD
Diluted Eps TTM
-2.07 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PRNAF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PRNAF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:10
Payout Ratio
–
Last Split Date
09.01.2023
Dividend Date
–
Stock Valuation PRNAF
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
113.9898
Price Sales TTM
2.6162
Enterprise Value EBITDA
0.7546
Price Book MRQ
1.1083
Financials PRNAF
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PRNAF
For 52 weeks
1.01 USD
5.41 USD
50 Day MA
1.31 USD
Shares Short Prior Month
9 668
200 Day MA
1.74 USD
Short Ratio
0.47
Shares Short
6 216
Short Percent
0.07 %
BeatStart